JPY 8530.0
(-0.92%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 139.61 Billion JPY | 32.49% |
2022 | 220.53 Billion JPY | 42.75% |
2021 | 154.49 Billion JPY | -22.2% |
2020 | 198.58 Billion JPY | 12.46% |
2019 | 176.58 Billion JPY | 63.05% |
2018 | 108.3 Billion JPY | 3.96% |
2017 | 104.18 Billion JPY | 3.0% |
2016 | 101.14 Billion JPY | -33.39% |
2015 | 151.83 Billion JPY | -27.61% |
2014 | 209.74 Billion JPY | 5.56% |
2013 | 198.7 Billion JPY | 17.12% |
2012 | 169.66 Billion JPY | 14.13% |
2011 | 148.66 Billion JPY | 26.52% |
2010 | 117.5 Billion JPY | 19.31% |
2009 | 98.48 Billion JPY | 7.61% |
2008 | 91.52 Billion JPY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q3 | 137.08 Billion JPY | 20.81% |
2024 Q2 | 113.47 Billion JPY | 39.1% |
2024 Q1 | 81.57 Billion JPY | 60.49% |
2023 Q2 | 53.91 Billion JPY | -29.78% |
2023 FY | 292.19 Billion JPY | 32.49% |
2023 Q1 | 76.77 Billion JPY | 116.43% |
2023 Q4 | 50.83 Billion JPY | -29.36% |
2023 Q3 | 71.95 Billion JPY | 33.48% |
2022 FY | 220.53 Billion JPY | 42.75% |
2022 Q1 | 55.85 Billion JPY | 1637.35% |
2022 Q2 | 63.94 Billion JPY | 14.49% |
2022 Q4 | 35.47 Billion JPY | -25.63% |
2022 Q3 | 47.7 Billion JPY | -25.4% |
2021 FY | 154.49 Billion JPY | -22.2% |
2021 Q1 | 50.09 Billion JPY | 86.31% |
2021 Q2 | 61.07 Billion JPY | 21.93% |
2021 Q3 | 46.96 Billion JPY | -23.11% |
2021 Q4 | -3.63 Billion JPY | -107.74% |
2020 Q1 | 53.94 Billion JPY | 159.92% |
2020 Q4 | 26.88 Billion JPY | -49.92% |
2020 Q3 | 53.68 Billion JPY | -16.2% |
2020 Q2 | 64.06 Billion JPY | 18.75% |
2020 FY | 198.58 Billion JPY | 12.46% |
2019 Q3 | 59.3 Billion JPY | -9.21% |
2019 Q1 | 31.2 Billion JPY | 170.06% |
2019 FY | 176.58 Billion JPY | 63.05% |
2019 Q4 | 20.75 Billion JPY | -65.0% |
2019 Q2 | 65.32 Billion JPY | 109.34% |
2018 Q4 | 11.55 Billion JPY | -37.35% |
2018 FY | 108.3 Billion JPY | 3.96% |
2018 Q1 | 34.76 Billion JPY | 274.02% |
2018 Q2 | 43.53 Billion JPY | 25.22% |
2018 Q3 | 18.44 Billion JPY | -57.64% |
2017 Q3 | 45.37 Billion JPY | 134.66% |
2017 FY | 104.18 Billion JPY | 3.0% |
2017 Q1 | 30.16 Billion JPY | 342.62% |
2017 Q2 | 19.33 Billion JPY | -35.9% |
2017 Q4 | 9.29 Billion JPY | -79.51% |
2016 FY | 101.14 Billion JPY | -33.39% |
2016 Q4 | -12.43 Billion JPY | -127.12% |
2016 Q3 | 45.85 Billion JPY | -5.07% |
2016 Q2 | 48.29 Billion JPY | 80.48% |
2016 Q1 | 26.76 Billion JPY | 460.11% |
2015 FY | 151.83 Billion JPY | -27.61% |
2015 Q1 | 51.58 Billion JPY | 0.0% |
2015 Q2 | 51.57 Billion JPY | -0.03% |
2015 Q3 | 43.9 Billion JPY | -14.88% |
2015 Q4 | 4.77 Billion JPY | -89.12% |
2014 Q2 | 65.56 Billion JPY | 396.29% |
2014 FY | 209.74 Billion JPY | 5.56% |
2014 Q4 | - JPY | -100.0% |
2014 Q3 | 71.08 Billion JPY | 8.42% |
2014 Q1 | 13.21 Billion JPY | -82.09% |
2013 Q4 | 73.77 Billion JPY | 20.59% |
2013 FY | 198.7 Billion JPY | 17.12% |
2013 Q1 | 38.24 Billion JPY | 0.7% |
2013 Q2 | 50.54 Billion JPY | 32.15% |
2013 Q3 | 61.17 Billion JPY | 21.04% |
2012 Q2 | 48.86 Billion JPY | 214.24% |
2012 Q3 | 44.57 Billion JPY | -8.77% |
2012 Q4 | 37.97 Billion JPY | -14.8% |
2012 FY | 169.66 Billion JPY | 14.13% |
2012 Q1 | 15.54 Billion JPY | -66.73% |
2011 Q2 | 46.35 Billion JPY | 126.84% |
2011 FY | 148.66 Billion JPY | 26.52% |
2011 Q4 | 46.73 Billion JPY | 16.77% |
2011 Q1 | 20.43 Billion JPY | -24.86% |
2011 Q3 | 40.02 Billion JPY | -13.67% |
2010 Q3 | 34.23 Billion JPY | -3.95% |
2010 Q1 | 7.54 Billion JPY | -75.35% |
2010 FY | 117.5 Billion JPY | 19.31% |
2010 Q4 | 27.19 Billion JPY | -20.55% |
2010 Q2 | 35.63 Billion JPY | 372.34% |
2009 Q3 | 35.31 Billion JPY | 41.23% |
2009 Q2 | 25 Billion JPY | 0.0% |
2009 Q4 | 30.61 Billion JPY | -13.32% |
2009 FY | 98.48 Billion JPY | 7.61% |
2008 FY | 91.52 Billion JPY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 95.84 Billion JPY | -45.669% |
Astellas Pharma Inc. | 124.6 Billion JPY | -12.043% |
Chugai Pharmaceutical Co., Ltd. | 439.17 Billion JPY | 68.21% |
Ono Pharmaceutical Co., Ltd. | 163.1 Billion JPY | 14.403% |
Santen Pharmaceutical Co., Ltd. | 38.54 Billion JPY | -262.243% |
JCR Pharmaceuticals Co., Ltd. | 7.53 Billion JPY | -1753.585% |
Daiichi Sankyo Company, Limited | 211.58 Billion JPY | 34.017% |
Perseus Proteomics Inc. | -894.72 Million JPY | 15703.831% |